Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10616962 | 0.92 | METAP2 (0.50) | METAP2METAP1PKN1PKN2GRIN1 | |
| SCHEMBL6442907 | 0.87 | METAP2 (0.41) | METAP2METAP1MAPK10PKN1PKN2 | |
| SCHEMBL10616910 | 0.85 | METAP2 (0.38) | METAP2METAP1MEN1KMT2AITK | |
| SCHEMBL6882471 | 0.84 | TRPV1 (0.33) | METAP2METAP1MEN1KMT2AGAA | |
| SCHEMBL6880554 | 0.84 | TRPV1 (0.37) | METAP2METAP1SMN1; SMN2TRPV1 | |
| SCHEMBL6878662 | 0.83 | CXCR4 (0.41) | METAP2METAP1PKN1PKN2MEN1 | |
| SCHEMBL10617520 | 0.81 | CBFB (0.40) | KMT2A | |
| SCHEMBL10620031 | 0.79 | METAP2 (0.52) | METAP2METAP1PKN1PKN2GRIN1 | |
| SCHEMBL10616921 | 0.78 | CBFB (0.48) | METAP2METAP1KMT2AGAASMN1; SMN2 | |
| SCHEMBL10617004 | 0.78 | CBFB (0.47) | METAP2METAP1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | claimed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | claimed |
| US-4045563-A | Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects | AB HASSLE (SW) | 1977-08-30 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-1572098-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | Sohn, Stearns & Stern (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| WO-2004034973-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | STERN WARREN (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | METAP2 1609/4885METAP1 2557/4885MAPK10 3630/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | METAP2 127/4885METAP1 359/4885MAPK10 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.